Subjects -> MEDICAL SCIENCES (Total: 8359 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (210 journals)
    - ANAESTHESIOLOGY (119 journals)
    - CARDIOVASCULAR DISEASES (329 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (228 journals)
    - DENTISTRY (288 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (119 journals)
    - ENDOCRINOLOGY (148 journals)
    - FORENSIC SCIENCES (41 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (182 journals)
    - GERONTOLOGY AND GERIATRICS (132 journals)
    - HEMATOLOGY (153 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (164 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (98 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2268 journals)
    - NURSES AND NURSING (356 journals)
    - OBSTETRICS AND GYNECOLOGY (202 journals)
    - ONCOLOGY (377 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (136 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (164 journals)
    - OTORHINOLARYNGOLOGY (80 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (270 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (152 journals)
    - PSYCHIATRY AND NEUROLOGY (813 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (190 journals)
    - RESPIRATORY DISEASES (102 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (78 journals)
    - SURGERY (393 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (150 journals)

CARDIOVASCULAR DISEASES (329 journals)                  1 2 | Last

Showing 1 - 200 of 329 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 5)
Acta Cardiologica     Hybrid Journal   (Followers: 2)
Acute Cardiac Care     Hybrid Journal   (Followers: 7)
Adipositas - Ursachen, Folgeerkrankungen, Therapie     Hybrid Journal  
AJP Heart and Circulatory Physiology     Hybrid Journal   (Followers: 12)
Aktuelle Kardiologie     Hybrid Journal   (Followers: 1)
American Heart Journal     Hybrid Journal   (Followers: 58)
American Journal of Cardiology     Hybrid Journal   (Followers: 67)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 17)
American Journal of Hypertension     Hybrid Journal   (Followers: 28)
Anales de Cirugia Vascular     Full-text available via subscription   (Followers: 1)
Anatolian Journal of Cardiology     Open Access   (Followers: 6)
Angiología     Full-text available via subscription  
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Angiology     Hybrid Journal   (Followers: 3)
Annales de Cardiologie et d'Angéiologie     Full-text available via subscription   (Followers: 1)
Annals of Noninvasive Electrocardiology     Hybrid Journal   (Followers: 1)
Annals of Pediatric Cardiology     Open Access   (Followers: 12)
AORTA     Open Access  
Archives of Cardiovascular Diseases     Full-text available via subscription   (Followers: 5)
Archives of Cardiovascular Diseases Supplements     Full-text available via subscription   (Followers: 3)
Archives of Cardiovascular Imaging     Open Access   (Followers: 2)
Archivos de cardiología de México     Open Access   (Followers: 1)
Argentine Journal of Cardiology (English edition)     Open Access   (Followers: 2)
Arquivos Brasileiros de Cardiologia     Open Access   (Followers: 1)
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 32)
Artery Research     Hybrid Journal   (Followers: 4)
ARYA Atherosclerosis     Open Access  
ASAIO Journal     Hybrid Journal   (Followers: 3)
ASEAN Heart Journal     Open Access   (Followers: 2)
Asian Cardiovascular and Thoracic Annals     Hybrid Journal   (Followers: 2)
Aswan Heart Centre Science & Practice Services     Open Access   (Followers: 1)
Atherosclerosis : X     Open Access  
Bangladesh Heart Journal     Open Access   (Followers: 3)
Basic Research in Cardiology     Hybrid Journal   (Followers: 10)
BMC Cardiovascular Disorders     Open Access   (Followers: 22)
Brain Circulation     Open Access   (Followers: 1)
British Journal of Cardiology     Full-text available via subscription   (Followers: 16)
Canadian Journal of Cardiology     Hybrid Journal   (Followers: 18)
Cardiac Cath Lab Director     Full-text available via subscription  
Cardiac Electrophysiology Review     Hybrid Journal   (Followers: 2)
Cardiocore     Full-text available via subscription   (Followers: 1)
Cardiogenetics     Open Access   (Followers: 3)
Cardiology     Full-text available via subscription   (Followers: 20)
Cardiology and Angiology: An International Journal     Open Access  
Cardiology and Therapy     Open Access   (Followers: 12)
Cardiology Clinics     Full-text available via subscription   (Followers: 14)
Cardiology in Review     Hybrid Journal   (Followers: 8)
Cardiology in the Young     Hybrid Journal   (Followers: 34)
Cardiology Journal     Open Access   (Followers: 6)
Cardiology Plus     Open Access   (Followers: 1)
Cardiology Research     Open Access   (Followers: 15)
Cardiology Research and Practice     Open Access   (Followers: 10)
Cardiopulmonary Physical Therapy Journal     Hybrid Journal   (Followers: 7)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Cardiothoracic Surgeon     Open Access  
CardioVasc     Full-text available via subscription   (Followers: 1)
Cardiovascular & Haematological Disorders - Drug Targets     Hybrid Journal   (Followers: 1)
Cardiovascular & Hematological Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 2)
CardioVascular and Interventional Radiology     Hybrid Journal   (Followers: 15)
Cardiovascular and Thoracic Open     Open Access  
Cardiovascular Diabetology     Open Access   (Followers: 10)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 14)
Cardiovascular Endocrinology & Metabolism     Hybrid Journal   (Followers: 1)
Cardiovascular Engineering     Hybrid Journal   (Followers: 1)
Cardiovascular Engineering and Technology     Hybrid Journal   (Followers: 1)
Cardiovascular Intervention and Therapeutics     Hybrid Journal   (Followers: 5)
Cardiovascular Journal     Open Access   (Followers: 6)
Cardiovascular Journal of Africa     Full-text available via subscription   (Followers: 5)
Cardiovascular Journal of South Africa     Full-text available via subscription   (Followers: 1)
Cardiovascular Medicine in General Practice     Full-text available via subscription   (Followers: 7)
Cardiovascular Pathology     Hybrid Journal   (Followers: 4)
Cardiovascular Regenerative Medicine     Open Access  
Cardiovascular Research     Hybrid Journal   (Followers: 15)
Cardiovascular Revascularization Medicine     Hybrid Journal   (Followers: 1)
Cardiovascular System     Open Access  
Cardiovascular Therapeutics     Open Access   (Followers: 1)
Cardiovascular Toxicology     Hybrid Journal   (Followers: 6)
Cardiovascular Ultrasound     Open Access   (Followers: 5)
Case Reports in Cardiology     Open Access   (Followers: 7)
Catheterization and Cardiovascular Interventions     Hybrid Journal   (Followers: 3)
Cerebrovascular Diseases     Full-text available via subscription   (Followers: 3)
Cerebrovascular Diseases Extra     Open Access  
Chest     Full-text available via subscription   (Followers: 100)
Choroby Serca i Naczyń     Open Access   (Followers: 1)
Circulation     Hybrid Journal   (Followers: 247)
Circulation : Cardiovascular Imaging     Hybrid Journal   (Followers: 15)
Circulation : Cardiovascular Interventions     Hybrid Journal   (Followers: 17)
Circulation : Cardiovascular Quality and Outcomes     Hybrid Journal   (Followers: 11)
Circulation : Genomic and Precision Medicine     Hybrid Journal   (Followers: 15)
Circulation : Heart Failure     Hybrid Journal   (Followers: 26)
Circulation Research     Hybrid Journal   (Followers: 36)
Cirugía Cardiovascular     Open Access  
Clínica e Investigación en Arteriosclerosis     Full-text available via subscription  
Clínica e Investigación en arteriosclerosis (English Edition)     Hybrid Journal  
Clinical and Experimental Hypertension     Hybrid Journal   (Followers: 3)
Clinical Cardiology     Hybrid Journal   (Followers: 11)
Clinical Hypertension     Open Access   (Followers: 5)
Clinical Medicine Insights : Cardiology     Open Access   (Followers: 6)
Clinical Research in Cardiology     Hybrid Journal   (Followers: 6)
Clinical Research in Cardiology Supplements     Hybrid Journal  
Clinical Trials and Regulatory Science in Cardiology     Open Access   (Followers: 4)
Congenital Heart Disease     Hybrid Journal   (Followers: 6)
Congestive Heart Failure     Hybrid Journal   (Followers: 4)
Cor et Vasa     Full-text available via subscription   (Followers: 1)
Coronary Artery Disease     Hybrid Journal   (Followers: 2)
CorSalud     Open Access  
Critical Pathways in Cardiology     Hybrid Journal   (Followers: 4)
Current Cardiology Reports     Hybrid Journal   (Followers: 7)
Current Cardiology Reviews     Hybrid Journal   (Followers: 4)
Current Cardiovascular Imaging Reports     Hybrid Journal   (Followers: 1)
Current Cardiovascular Risk Reports     Hybrid Journal  
Current Heart Failure Reports     Hybrid Journal   (Followers: 5)
Current Hypertension Reports     Hybrid Journal   (Followers: 6)
Current Hypertension Reviews     Hybrid Journal   (Followers: 6)
Current Opinion in Cardiology     Hybrid Journal   (Followers: 14)
Current Problems in Cardiology     Hybrid Journal   (Followers: 3)
Current Research : Cardiology     Full-text available via subscription   (Followers: 1)
Current Treatment Options in Cardiovascular Medicine     Hybrid Journal   (Followers: 1)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 5)
CVIR Endovascular     Open Access   (Followers: 1)
Der Kardiologe     Hybrid Journal   (Followers: 2)
Echo Research and Practice     Open Access   (Followers: 2)
Echocardiography     Hybrid Journal   (Followers: 4)
Egyptian Heart Journal     Open Access   (Followers: 2)
Egyptian Journal of Cardiothoracic Anesthesia     Open Access  
ESC Heart Failure     Open Access   (Followers: 4)
European Heart Journal     Hybrid Journal   (Followers: 67)
European Heart Journal - Cardiovascular Imaging     Hybrid Journal   (Followers: 10)
European Heart Journal - Cardiovascular Pharmacotherapy     Full-text available via subscription   (Followers: 3)
European Heart Journal - Quality of Care and Clinical Outcomes     Hybrid Journal  
European Heart Journal : Acute Cardiovascular Care     Hybrid Journal   (Followers: 1)
European Heart Journal : Case Reports     Open Access   (Followers: 1)
European Heart Journal Supplements     Hybrid Journal   (Followers: 8)
European Journal of Cardio-Thoracic Surgery     Hybrid Journal   (Followers: 9)
European Journal of Cardio-Thoracic Surgery Supplements     Full-text available via subscription   (Followers: 2)
European Journal of Cardiovascular Nursing     Hybrid Journal   (Followers: 5)
European Journal of Heart Failure     Hybrid Journal   (Followers: 14)
European Journal of Preventive Cardiology.     Hybrid Journal   (Followers: 6)
European Stroke Organisation     Hybrid Journal   (Followers: 3)
Experimental & Translational Stroke Medicine     Open Access   (Followers: 8)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 3)
Folia Cardiologica     Open Access  
Forum Zaburzeń Metabolicznych     Hybrid Journal  
Frontiers in Cardiovascular Medicine     Open Access   (Followers: 1)
Future Cardiology     Hybrid Journal   (Followers: 6)
General Thoracic and Cardiovascular Surgery     Hybrid Journal   (Followers: 3)
Global Cardiology Science and Practice     Open Access   (Followers: 5)
Global Heart     Hybrid Journal   (Followers: 3)
Heart     Hybrid Journal   (Followers: 48)
Heart and Mind     Open Access  
Heart and Vessels     Hybrid Journal  
Heart Failure Clinics     Full-text available via subscription   (Followers: 2)
Heart Failure Reviews     Hybrid Journal   (Followers: 3)
Heart India     Open Access   (Followers: 2)
Heart International     Full-text available via subscription  
Heart Rhythm     Hybrid Journal   (Followers: 11)
Heart Views     Open Access   (Followers: 2)
HeartRhythm Case Reports     Open Access  
Hellenic Journal of Cardiology     Open Access   (Followers: 1)
Herz     Hybrid Journal   (Followers: 3)
High Blood Pressure & Cardiovascular Prevention     Full-text available via subscription   (Followers: 2)
Hypertension     Full-text available via subscription   (Followers: 23)
Hypertension in Pregnancy     Hybrid Journal   (Followers: 9)
Hypertension Research     Hybrid Journal   (Followers: 5)
Ibrahim Cardiac Medical Journal     Open Access  
IJC Heart & Vessels     Open Access   (Followers: 1)
IJC Heart & Vasculature     Open Access   (Followers: 1)
IJC Metabolic & Endocrine     Open Access   (Followers: 1)
Indian Heart Journal     Open Access   (Followers: 5)
Indian Journal of Cardiovascular Disease in Women WINCARS     Open Access  
Indian Journal of Thoracic and Cardiovascular Surgery     Hybrid Journal  
Indian Pacing and Electrophysiology Journal     Open Access   (Followers: 1)
Innovations : Technology and Techniques in Cardiothoracic and Vascular Surgery     Hybrid Journal   (Followers: 1)
Insuficiencia Cardíaca     Open Access  
Interactive CardioVascular and Thoracic Surgery     Hybrid Journal   (Followers: 7)
International Cardiovascular Forum Journal     Open Access  
International Journal of Angiology     Hybrid Journal   (Followers: 2)
International Journal of Cardiology     Hybrid Journal   (Followers: 18)
International Journal of Cardiovascular and Cerebrovascular Disease     Open Access   (Followers: 2)
International Journal of Cardiovascular Imaging     Hybrid Journal   (Followers: 2)
International Journal of Cardiovascular Research     Hybrid Journal   (Followers: 6)
International Journal of Heart Rhythm     Open Access  
International Journal of Hypertension     Open Access   (Followers: 8)
International Journal of Hyperthermia     Open Access  
International Journal of Stroke     Hybrid Journal   (Followers: 30)
International Journal of the Cardiovascular Academy     Open Access  
Interventional Cardiology Clinics     Full-text available via subscription   (Followers: 2)
Interventional Cardiology Review     Full-text available via subscription  
JACC : Basic to Translational Science     Open Access   (Followers: 5)
JACC : Cardiovascular Imaging     Hybrid Journal   (Followers: 18)
JACC : Cardiovascular Interventions     Hybrid Journal   (Followers: 17)
JACC : Heart Failure     Full-text available via subscription   (Followers: 14)
JAMA Cardiology     Hybrid Journal   (Followers: 28)
JMIR Cardio     Open Access  
Jornal Vascular Brasileiro     Open Access  
Journal of Clinical & Experimental Cardiology     Open Access   (Followers: 5)
Journal of Arrhythmia     Open Access  
Journal of Cardiac Critical Care TSS     Open Access   (Followers: 1)
Journal of Cardiac Failure     Hybrid Journal   (Followers: 1)

        1 2 | Last

Similar Journals
Journal Cover
Archives of Cardiovascular Diseases
Journal Prestige (SJR): 1.203
Citation Impact (citeScore): 2
Number of Followers: 5  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1875-2136 - ISSN (Online) 1875-2128
Published by Elsevier Homepage  [3161 journals]
  • Four-dimensional flow cardiovascular magnetic resonance: Towards accurate
           flow quantification'
    • Abstract: Publication date: Available online 21 March 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Jérôme Garot
       
  • Reply to the letter about the position paper concerning the competence,
           performance and environment required in the practice of complex ablation
           procedures
    • Abstract: Publication date: Available online 18 March 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Philippe Maury, Pascal Defaye, Didier Klug, Christine Alonso, Frederic Anselme, Laurent Fauchier, Estelle Gandjbakhch, Daniel Gras, Jean-Sylvain Hermida, Gabriel Laurent, Jacques Mansourati, Eloi Marijon, Frederic Sacher, Jérôme Taieb, Serge Boveda, Olivier Piot, Nicolas Sadoul, Working Group on Pacing, Electrophysiology of the French Society of Cardiology
       
  • Management of antiplatelet therapy for non-elective invasive procedures or
           bleeding complications: Proposals from the French Working Group on
           Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis
           and Haemostasis (GFHT), in collaboration with the French Society for
           Anaesthesia and Intensive Care (SFAR)
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Anne Godier, Dephine Garrigue, Dominique Lasne, Pierre Fontana, Fanny Bonhomme, Jean-Philippe Collet, Emmanuel de Maistre, Brigitte Ickx, Yves Gruel, Mikael Mazighi, Philippe Nguyen, André Vincentelli, Pierre Albaladejo, Thomas Lecompte, French Working Group on Perioperative Haemostasis (GIHP)SummaryThe French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR), drafted up-to-date proposals on the management of antiplatelet therapy for non-elective invasive procedures or bleeding complications. The proposals were discussed and validated by a vote; all proposals could be assigned with a high strength. Management of oral antiplatelet agents in emergency settings requires knowledge of their pharmacokinetic and pharmacodynamic parameters, evaluation of the degree of alteration of haemostatic competence and the associated bleeding risk. Platelet function testing may be considered. When antiplatelet agent-induced bleeding risk may worsen the prognosis, measures should be taken to neutralize antiplatelet therapy, by considering not only the efficacy of available means (which can be limited for prasugrel and even more for ticagrelor), but also the risks that these means expose the patient to. The measures include platelet transfusion at the appropriate dose and haemostatic agents (tranexamic acid; recombinant activated factor VII for ticagrelor). When possible, postponing non-elective invasive procedures at least for a few hours until the elimination of the active compound (which could compromise the effect of transfused platelets) or, if possible, for a few days (reduction of the effect of antiplatelet agents) should be considered.RésuméLe Groupe d’intérêt en hémostase périopératoire (GIHP) et le Groupe français d’études sur l’hémostase et la thrombose (GFHT) en collaboration avec la Société française d’anesthésie-réanimation (SFAR) ont fait des propositions sur la gestion des agents antiplaquettaires (AAP) en cas de procédure invasive non programmée ou d’hémorragie. Ces propositions ont été discutées puis validées par un vote, elles font toutes l’objet d’un accord fort. La gestion des AAP en urgence nécessite de prendre en compte leurs caractéristiques pharmacocinétiques et pharmacodynamiques, d’évaluer l’affaiblissement de la compétence hémostatique liée aux AAP et le risque hémorragique qu’il entraîne. Les tests fonctionnels plaquettaires peuvent aider à cette évaluation. Lorsque le risque hémorragique lié aux AAP est susceptible d’aggraver le pronostic, la neutralisation des AAPdoit être envisagée, en prenant en compte l’efficacité des moyens de neutralisation (qui sont limités pour le prasugrel et le ticagrelor) mais aussi les risques associés à ces moyens. Ceux-ci incluent la transfusion plaquettaire, à des doses adaptées à l’AAP considéré, et les agents hémostatiques (facteur VII activé recombinant et acide tranexamique). Pour les procédures invasives non programmées, le report de quelques jours, voire de quelques heures, doit être envisagé lorsqu’il ne compromet pas le pronostic vital ou fonctionnel du patient, jusqu’à élimination ou diminution suffisante de l’effet de l’AAP ou de son métabolite actif.
       
  • Evolution of chronic kidney disease after surgical aortic valve
           replacement or transcatheter aortic valve implantation
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Adrien Reuillard, Cyril Garrouste, Bruno Pereira, Kasra Azarnoush, Géraud Souteyrand, Julien Aniort, Andrea Innorta, Guillaume Clerfond, Anne Elisabeth Heng, Romain Eschalier, Pascal Motreff, Nicolas CombaretSummaryBackgroundImmediate improvement in kidney function has been reported after surgical aortic valve replacement or transcatheter aortic valve implantation. Long-term data, however, are not available.AimTo assess the evolution of kidney function in chronic kidney disease stage 3b–5, 1 year after surgical aortic valve replacement or transcatheter aortic valve implantation.MethodsAll patients with chronic kidney disease stage 3b–5 undergoing surgical aortic valve replacement or transcatheter aortic valve implantation for aortic stenosis in a single centre were included. Kidney function was assessed 1 year postprocedure. Improvement or deterioration in estimated glomerular filtration rate was defined by an increase or decrease of 5 mL/min/1.73 m2, respectively.ResultsOverall, 127 procedures were analysed (54 surgical aortic valve replacements and 73 transcatheter aortic valve implantations). Kidney function improved in 51% of patients at 1 year (45% of the surgical aortic valve replacement group versus 57% of the transcatheter aortic valve implantation group; P = 0.21), and deteriorated in only 14% of patients at 1 year (18% of the surgical aortic valve replacement group versus 10% of the transcatheter aortic valve implantation group; P = 0.22). Almost a quarter of patients (23%) had an improvement in estimated glomerular filtration rate of > 15 mL/min/1.73 m2, and this was consistent at later follow-up. Few patients went onto chronic dialysis at 1 year (three after surgical aortic valve replacement and one after transcatheter aortic valve implantation). Acute kidney injury was an independent prognostic factor for long-term deterioration in kidney function (odds ratio 2.1, 95% confidence interval 1.4–3.6; P = 0.006).ConclusionAortic valve replacement, whether by surgical aortic valve replacement or transcatheter aortic valve implantation, improved estimated glomerular filtration rate at 1 year in more than half of patients with chronic kidney disease stage 3b–5.RésuméContexteUne amélioration de la fonction rénale immédiatement après un remplacement valvulaire aortique chirurgical (RVAC) ou un remplacement aortique valvulaire percutané (TAVI) a été observée. En revanche, des données à plus long terme ne sont pas décrites.ObjectifÉvaluer l’impact d’un RVAC ou d’un TAVI à un an sur la fonction rénale d’insuffisants rénaux chroniques (IRC) de stade 3b à 5.MéthodesTous les patients IRC de stade 3b à 5 bénéficiant d’un RVAC ou d’un TAVI dans un centre étaient inclus. La fonction rénale était évaluée durant l’année suivant la procédure. Le critère de jugement principal était une amélioration ou une dégradation à un an du débit de filtration glomérulaire estimé (DFGe) de 5 mL/min/1,73 m2.Résultats127 patients ont été inclus (54 RVAC et 73 TAVI). Le DFGe s’est amélioré à un an parmi 51 % des patients (RVAC 45 % vs TAVI 57 % ; p = 0,21) et détérioré chez seulement 14 % (RVAC 18 % vs TAVI 10 % ; p = 0,22). Presque un quart des patients ont présenté une amélioration de plus de 15 mL/min/1,73 m2. Seulement 4 patients ont nécessité une mise en dialyse chronique à un an (3 vs 1 patient après RVAC et TAVI, respectivement). L’insuffisance rénale aiguë était un facteur pronostique indépendant d’une détérioration de la fonction rénale à un an (OR 2,1, IC95 % 1,4–3,6 ; p = 0,006).ConclusionUn RVAC ou un TAVI a permis une amélioration significative de la fonction rénale à un an chez plus de la moitié des patients IRC stade 3b à 5.
       
  • Occurrence of significant long PR intervals in patients implanted for
           sinus node dysfunction and monitored with SafeR™: The PRECISE study
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Jérôme Taieb, Pierre Le Franc, Pierre Khattar, Ghassan Moubarak, Hervé Gorka, Jean-Philippe Godenir, Philippe Deutsch, Bruno Degand, Ayman Al Daoud, Jean-Philippe Elkaim, Nathalie Elbaz, Sandrine Merlo, Nicolas LelloucheSummaryBackgroundLong PR intervals may increase cardiovascular complications, including atrial fibrillation. In pacemakers, the SafeR™ mode monitors PR intervals, switching from AAI to DDD when criteria for atrioventricular block are met.AimsThe PRECISE study evaluated the incidence and predictors of long PR intervals and their association with incident atrial fibrillation after 1 year in patients implanted for sinus node dysfunction and free from significant conduction disorders at baseline.MethodsThis French, prospective, multicentre, observational trial enrolled patients implanted with a REPLY™ dual-chamber pacemaker. Pacemaker memory recorded long PR intervals (defined as first-degree atrioventricular block mode switches occurring after six consecutive PR/AR intervals ≥ 350/450 ms) and atrial fibrillation incidence (fallback mode switch > 1 minute/day). Predictors were identified from baseline variables (age, sex, AR and PR intervals, atrial rhythm disorder and medication) using logistic regression.ResultsOf 291 patients with sinus node dysfunction enrolled, 214 were free from significant conduction disorders at baseline (mean age 79 ± 8 years; 44% men; PR/AR intervals  1 minute par jour. La valeur prédictive de l’allongement du PR des caractéristiques à l’inclusion (âge, sexe, intervalles AR et PR, maladie de rythme auriculaire, médicaments) est analysée par la méthode de régression logistique.RésultatsParmi 291 patients inclus, 214 patients (âge 79 ± 8 ans ; mâle 44 %) ne présentaient pas de troubles de conduction à l’inclusion (PR/AR 
       
  • The best DEFENSE for high-risk patent foramen ovale: An updated
           meta-analysis of six randomized trials
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Damianos G. Kokkinidis, Leonidas Palaiodimos, Ioannis Mastoris, Dimitrios Karamanis, Robert T. Faillace
       
  • Closure of patent foramen ovale and “cryptogenic” stroke:
           What's new, what's next'
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Jean-Louis Mas
       
  • Automated external defibrillator use in out-of-hospital cardiac arrest:
           Current limitations and solutions
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Clémence Delhomme, Mario Njeim, Emilie Varlet, Louis Pechmajou, Nordine Benameur, Pascal Cassan, Clément Derkenne, Daniel Jost, Lionel Lamhaut, Eloi Marijon, Xavier Jouven, Nicole KaramSummaryOut-of-hospital sudden cardiac arrest (OHCA) is a major public health issue, with a survival rate at hospital discharge that remains below 10% in most cities, despite huge investments in this domain. Early basic life support (BLS) and early defibrillation using automated external defibrillators (AEDs) stand as key elements for improving OHCA survival rate. Nevertheless, the use of AEDs in OHCA remains low, for a variety of reasons, including the number, accessibility and ease of locating AEDs, as well as bystanders’ awareness of BLS manœuvres and of the need to use AEDs. Several measures have been proposed to improve the rate of AED use, including optimization of AED deployment strategies as well as the use of drones to bring the AEDs to the OHCA scene and of mobile applications to locate the nearest AED. If they are to be effective, these measures should be combined with large communication campaigns on OHCA, and wide-scale education of the public in BLS and AEDs, to reduce the burden of OHCA.RésuméL’arrêt cardiorespiratoire (ACR) extrahospitalier constitue un véritable problème de santé publique, avec un taux de survie qui reste inférieur à 10 % dans la plupart des pays, malgré de considérables investissements dans ce domaine. La réanimation précoce et une défibrillation précoce grâce à l’usage des défibrillateurs automatiques externes (DAE) ont été identifiées comme des éléments clés pour améliorer la survie des ACR. Pourtant, le taux d’utilisation des DAEs dans les ACR reste faible. Plusieurs limites empêchent une plus ample utilisation des DAE, dont leur nombre, leur accessibilité et la facilité de leur localisation, ainsi que l’éducation des témoins aux gestes qui sauvent et à la nécessité d’utiliser un DAE. Plusieurs pistes ont été testées pour améliorer ces différents paramètres, incluant une optimisation du déploiement des DAEs, ainsi que l’utilisation de drones permettant de ramener les DAEs sur le site d’ACR et d’applications permettant de localiser le DAE le plus proche. Ces mesures doivent systématiquement être associées à de vastes campagnes de communication sur la mort subite et à une éducation du grand public aux manœuvres de réanimation et à l’intérêt de l’utilisation des DAEs.Graphical abstractGraphical abstract for this article
       
  • Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as
           biomarkers of acute kidney injury after ST-segment elevation myocardial
           infarction treated by percutaneous coronary intervention
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Lee S. Nguyen, Vincent Spagnoli, Mathieu Kerneis, Marie Hauguel-Moreau, Olivier Barthélémy, Jean-Philippe Collet, Gilles Montalescot, Johanne SilvainSummaryBackgroundTwo biomarkers of early acute kidney injury − plasmatic neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C − are not used in routine clinical practice in patients with ST-segment elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention (PCI) because of a lack of supporting data.AimsTo evaluate the predictive value of NGAL and cystatin C regarding the incidence of contrast-induced acute kidney injury (CI-AKI) and clinical outcomes after STEMI in patients treated by primary PCI.MethodsPlasmatic NGAL and cystatin C were measured on admission, before any contrast exposure, in 701 unselected patients with STEMI. Associations between biomarker concentrations and incidence of CI-AKI (assessed at 48 h), haemodialysis requirement at 1 year and all-cause mortality at 1 year were assessed by logistic regression analyses and receiver operating characteristic area under the curve analysis (c-statistic). Discrimination performance comparison was performed using the DeLong test.ResultsNGAL and cystatin C had mild discrimination regarding CI-AKI, with c-statistics of 0.60 (P = 0.001) and 0.60 (P = 0.002), respectively. Combining NGAL and cystatin C did not improve their discrimination (c-statistic 0.61; P = 0.001). There was no significant difference in discrimination between NGAL, cystatin C and baseline creatinine (P = 0.57). Regression analyses showed no independent association between NGAL and CI-AKI, haemodialysis or 1-year mortality. Similarly, cystatin C was not associated with these clinical outcomes.ConclusionsIn this cohort of patients with STEMI treated by primary PCI, plasmatic NGAL and cystatin C did not provide additional value regarding CI-AKI prediction compared with known risk factors such as baseline creatinine.
       
  • Sex-related risks of recurrence of atrial fibrillation after ablation:
           Insights from the Guangzhou Atrial Fibrillation Ablation Registry
    • Abstract: Publication date: March 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 3Author(s): Hai Deng, Alena Shantsila, Pi Guo, Tatjana S. Potpara, Xianzhang Zhan, Xianhong Fang, Hongtao Liao, Yang Liu, Wei Wei, Lu Fu, Yumei Xue, Shulin Wu, Gregory Y.H. LipSummaryBackgroundFemale sex has been linked with worse prognosis in patients with atrial fibrillation (AF). Clinical risk stratification of women with AF may help decision-making before catheter ablation (CA).AimTo evaluate arrhythmia outcomes and the predictive value of clinical scores for arrhythmia recurrence in a large cohort of Chinese patients with AF undergoing CA.MethodsA total 1410 of patients (68.1% men) who underwent AF ablation with scheduled follow-up were analysed retrospectively. Baseline characteristics and ablation outcome were compared between men and women. The predictive values of risk scoring systems for AF recurrence were assessed in women.ResultsRecurrence, early recurrence and complications after CA were similar in women and men over similar follow-up periods (20.7 ± 8.0 vs 20.7 ± 9.1 months; P > 0.05). Compared with men, women with AF recurrence were older and had a larger left atrial diameter (LAD), less paroxysmal AF, lower left ventricular ejection fraction, lower estimated glomerular filtration rate (eGFR) and higher serum concentrations of B-type natriuretic peptide (BNP) and C-reactive protein (CRP) (all P 
       
  • Transcatheter pulmonary valvuloplasty in neonates with pulmonary atresia
           and intact ventricular septum
    • Abstract: Publication date: Available online 20 February 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Sébastien Hascoët, Suzanne Borrhomée, Nabil Tahhan, Jérôme Petit, Angele Boet, Lucile Houyel, Emmanuel Lebret, Mohammed Ly, Régine Roussin, Emre Belli, Virginie Lambert, Daniela LauxSummaryBackgroundTranscatheter pulmonary valvuloplasty in neonates with pulmonary atresia and intact ventricular septum (PA-IVS) or duct-dependent pulmonary valve stenosis (DD-PVS) has become a reasonable alternative to surgical right ventricle decompression.AimTo investigate mid-term outcomes following pulmonary valvuloplasty.MethodsSixty-five neonates with PA-IVS (n = 29) or DD-PVS (n = 36) (median age 4 days; mean weight 3.0 kg) undergoing pulmonary valvuloplasty were reviewed retrospectively. Procedural data and clinical outcomes were assessed.ResultsPulmonary valvuloplasty was successful in 59 patients (90.8%). Preterm birth, larger tricuspid valve annulus diameter and PA-IVS correlated with procedural failure. Eleven patients (18.6%) required a Blalock-Taussig shunt during early follow-up, despite valvuloplasty. These neonates had smaller tricuspid and pulmonary valve annulus Z-scores (–1.9 vs. –0.8 [p = 0.04] and –2.5 vs. –0.9 [P = 0.005], respectively) and a higher incidence of “bipartite” right ventricle (P = 0.02). Mean follow-up was 5.4 ± 3.3 years. Mortality after successful valvuloplasty was 8.5% (n = 5). Among the 54 survivors, biventricular repair was achieved in 52 patients (96.3%), including nine with a previous Blalock-Taussig shunt. The cumulative rate of subsequent surgery (excluding Blalock-Taussig shunt) was 13.7% (95% confidence interval 6.8–26.7%) and 16.4% (95% confidence interval 8.5–30.4%) at 2 and 4 years, respectively. Secondary surgery was significantly more frequent in PA-IVS compared with DD-PVS, and in neonates with a Blalock-Taussig shunt (P = 0.003 and 0.01, respectively).ConclusionsSelected neonates with DD-PVS or PA-IVS managed by transcatheter pulmonary valvuloplasty had a good mid-term outcome. In neonates with a borderline small right ventricle, a hybrid strategy with a supplementary source of pulmonary blood flow can be efficient to achieve biventricular repair.RésuméContexteLa valvuloplastie pulmonaire percutanée est devenue une alternative à la décompression chirurgicale du ventricule droit chez les nouveau-nés ayant une atrésie pulmonaire à septum intact (APSI) ou une sténose valvulaire pulmonaire critique (SVPC).ObjectifNous avons étudié les résultats de cette procédure et le devenir à moyen terme.MéthodesSoixante-cinq nouveau-nés ayant une APSI (n = 29) ou une SVPC (n = 36) (âge médian 4 j ; poids moyen 3 kg) et ayant eu une valvuloplastie pulmonaire percutanée ont été rétrospectivement inclus. Les données des procédures et le devenir clinique à moyen terme ont été étudiés.RésultatsLa valvuloplastie pulmonaire percutanée a été réussie dans 59 cas (90,8 %). Les prématurés, un anneau tricuspide large et l’APSI était corrélés au risque d’échec. Onze patients (18,6 %) ont nécessité une anastomose de Blalock-Taussig durant le suivi précoce malgré la valvuloplastie. Ces nouveau-nés avaient des Z-scores des anneaux tricuspide et pulmonaire plus bas (–1,9 vs –0,8 [p = 0,04] et –2,5 vs –0,9 [p = 0,005], respectivement) et une incidence plus élevée de ventricule droit bipartite (p = 0,02). Le suivi moyen a été de 5,4 ± 3,3 ans. La mortalité après valvuloplastie pulmonaire a été de 8,5 % (n = 5). Parmi les 54 survivants, 52 (96,3 %) ont évolué vers une circulation biventriculaire, incluant 9 patients avec précédemment une anastomose de Blalock-Taussig. L’incidence cumulée d’une réintervention chirurgicale (autre qu’une anastomose de Blalock-Taussig) durant le suivi était de 13,7 % (IC95 % 6,8–26,7 %) et 16,4 % (IC95 % 8,5–30,4 %) à 2 et 4 ans respectivement. Une réintervention était plus fréquente chez les nouveau-nés avec APSI et chez les nouveau-nés ayant eu une anastomose de Blalock-Taussig (p = 0,003 et 0,01, respectivement).ConclusionsLes nouveau-nés ayant une APSI ou une SVPC sélectionnés pour la valvuloplastie pulmonaire percutanée ont un bon devenir à moyen terme. Chez les nouveau-nés avec un ventricule droit moyennement hypoplasique, une stratégie hybride avec source additionnelle de flux pulmonaire est efficace pour obtenir une circulation biventriculaire à terme.
       
  • Which high-sensitivity troponin variable best characterizes infarct size
           and microvascular obstruction'
    • Abstract: Publication date: Available online 15 February 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Mathieu Schaaf, Fabien Huet, Mariama Akodad, Anne-Marie Gorce-Dupuy, Jérôme Adda, Jean-Christophe Macia, Delphine Delseny, Florence Leclercq, Jean-Paul Cristol, Gregory Marin, Nathan Mewton, François RoubilleSummaryBackgroundThe link between hs-Tn and infarct size has already been proved in several articles. However few is known about the kinetic of the troponin and its link to the infarct characteristics, likewise MVO. Our primary objective was to study which hs-Tn characterizes the best infarction.Methods and resultsWe identified 29 consecutive STEMI patients to study. The kinetics of hs-TnT (Roche) and two different TnIs (hs-TnI from Abbott, s-TnI from Siemens) were evaluated for all patients. Area under curves (AUC), first peak (FP) and second peak (SP), for hs-TnT, were compared to IS and MVO size using contrast-enhanced cardiac magnetic resonance. For IS, statistically SP of hs-TnT presented the best correlation compared to other peak values [r = 0.9 vs. 0.73 for FP hs-TnT; vs. 0.69 for hs-TnI; vs. 0.57 for s-TnI; respectively P 
       
  • Ten-year follow-up of unreplaced Valsalva sinuses after aortic valve
           replacement in bicuspid aortic valve disease
    • Abstract: Publication date: Available online 14 February 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Ramzi Abi Akar, Noémie Tence, Jérome Jouan, Wassim Borik, Philippe Menasché, Jean-Noel Fabiani, Christian Latremouille, Paul AchouhSummaryBackgroundAortopathy is common in patients with bicuspid aortic valve (BAV).AimTo evaluate the fate of unreplaced Valsalva sinuses in patients with BAV, 10 years after aortic valve replacement (AVR) with or without replacement of the ascending aorta (RAA).MethodsWe retrospectively reviewed all surgical patients with BAV who were operated on between January 2005 and December 2007. Patients who underwent AVR with or without RAA were included. Surgical data were entered prospectively. Ten-year clinical and echocardiographic follow-up data as well as survival data were collected by contacting the patients and their personal cardiologists, and by consulting the French national mortality registry. Overall, 25% of the patients had computed tomography angiographic assessment of the aortic root at follow-up.ResultsA total of 133 patients with BAV were operated on within the selected period. Thirty-two patients did not meet the inclusion criteria, and had primary Valsalva sinus surgery. Twenty-four patients underwent AVR with RAA and 77 patients had isolated AVR; all of these 101 patients were included in the study. The median follow-up was 9 years (up to 12 years). During follow-up, eight patients (7.9%) underwent late reoperation; two of them (2.0%) required root surgery. Ten-year freedom from reoperation was 86.2 ± 4.7%. Ten-year freedom from dilatation of the Valsalva sinuses (>45 mm) was 86.6 ± 5.2%. Ten-year cumulative survival was 83.5 ± 4%.ConclusionsAscending aorta and Valsalva sinuses seem to have different fates after AVR in BAV disease. When the Valsalva sinuses are not dilated at the initial surgery, the risk of secondary dilatation at 10 years is low. Preservation of the sinuses is therefore justified in patients with BAV with a non-dilated root. In BAV with isolated aortic insufficiency, a more aggressive approach may be justified, especially in young patients.RésuméContexteL’atteinte de la paroi aortique est fréquente chez les patients ayant une valve aortique bicuspide. Nous avons évalué le devenir des sinus de Valsalva non remplacés chez les patients porteurs de bicuspidie aortique 10 ans un remplacement de la valve aortique (RVA), avec ou sans remplacement de l’aorte ascendante (RAA).MéthodeNous avons examiné rétrospectivement tous les patients ayant une bicuspidie, opérés entre janvier 2005 et décembre 2007. Les patients qui ont bénéficié d’un RVA avec ou sans RAA ont été inclus. Les données chirurgicales ont été entrées prospectivement. Les données de suivi clinique et échocardiographique à dix ans ainsi que les données de survie ont été collectées en contactant les patients, leurs cardiologues et en consultant le Répertoire national français d’identification des personnes physiques (RNIPP) respectivement. Un quart des patients avaient un suivi de la racine aortique par angioscanner.RésultatsCent trente-trois patients avec bicuspidie aortique ont été opérés durant cette période. Trente-deux malades ne répondaient pas au critères d’inclusion. Vingt-quatre patients ont été opérés de RVA avec RAA et 77 patients ont bénéficiés de RVA isolé. Le temps de suivi médian était de 9 ans et le suivi maximal de 12 ans. Durant le suivi, 8 patients (7,9 %) ont été réopérés dont deux pour dilatation du culot aortique (1,9 %). L’absence de réopération et l’absence de dilatation des sinus de Valsalva (> 45 mm) à 10 ans était de 86.2 ± 4.7 % et 86.6 ± 5.2 % respectivement. La survie cumulée à 10 ans était de 83.5 ± 4 %.ConcluisonL’aorte ascendante et les sinus de Valsalva semblent avoir un destin différent après remplacement de la valve aortique dans la bicuspidie. Lorsque les sinus de Valsalva ne sont pas dilatés au moment de la chirurgie initiale, le risque de dilatation secondaire à 10 ans est faible. La conservation des sinus de Valsalva est donc justifiée chez les patients ayant une valve aortique bicuspide sans dilatation du culot aortique. Dans le cas de valve bicuspide avec insuffisance aortique isolée, une approche plus agressive pourrait être justifiée, notamment chez les patients jeunes.
       
  • Prognosis of severe congenital heart diseases: Do we overestimate the
           impact of prenatal diagnosis'
    • Abstract: Publication date: Available online 2 February 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Marie Vincenti, Sophie Guillaumont, Beatrice Clarivet, Valerie Macioce, Thibault Mura, Pierre Boulot, Gilles Cambonie, Pascal AmedroSummaryBackgroundPrenatal diagnosis of congenital heart disease (CHD) is controversial because of unclear benefits in terms of morbidity and mortality, and issues with healthcare costs and organization.AimTo compare, in children with severe CHD, 1-year morbidity and mortality between prenatal and postnatal diagnosis groups.MethodsAll pregnancies and children aged 
       
  • Left superior vena cava draining into the left atrium: Clinical entities,
           diagnosis and surgical treatment
    • Abstract: Publication date: February 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 2Author(s): Juan M. Aguilar, Fernando Rodríguez-Serrano, Andrea Ferreiro-Marzal, María Esteban-Molina, Antonio Gabucio, Enrique García, Lorenzo Boni, José M. GarridoSummaryLeft superior vena cava draining into the left atrium in the absence of coronary sinus is an anomaly that can appear in heterotaxy syndrome and unroofed coronary sinus syndrome. Regardless of the origin of these syndromes, biventricular repair can be done through rerouting by intracardiac procedures or through disconnection-reconnection of the left superior vena cava to the right atrium or right superior vena cava by extracardiac procedures. Different techniques can be used for this purpose, each of which has its own advantages and limitations. Therefore, appropriate selection is necessary to obtain the best results for each patient, and many factors, such as patient anatomy, age, associated cardiomyopathies, etc., have to be considered. In this review, we focus on heterotaxy and unroofed coronary sinus syndromes, associated cardiomyopathies, the state-of-the-art in their surgical treatment and our results in a sample of 10 patients. Our experience highlights the importance of accurate diagnosis and specific selection of surgical technique for the management of biventricular repair in patients with left superior vena cava draining into the left atrium in the absence of coronary sinus.RésuméLa veine cave supérieure gauche en drainant à l’oreillette gauche en l’absence de sinus coronaire est une anomalie qui peut apparaître dans le syndrome d’hétérotaxie et le syndrome de l’agénésie du toit du sinus coronaire. Indépendamment de l’origine de ces syndromes, la réparation biventriculaire peut être effectuée par réacheminement par des procédures intracardiaques ou par déconnexion-reconnexion de la veine cave supérieure gauche à l’oreillette droite ou à la veine cave supérieure droite par des procédes extracardiaques. Il y a différentes techniques qui pourraient être utilisées à cette fin et toutes ont leurs avantages et leurs limites. Par conséquent, une sélection appropriée est déterminante afin d’obtenir les meilleurs résultats pour chaque patient, sans oublier de prendre en compte de nombreux facteurs tels que l’anatomie du patient, son âge, les cardiomyopathies associées, etc. Dans cette révision, nous nous intéressons aux cardiomyopathies associées aux syndromes coronariens hétérotaxiques et non-affleurés, aux traitements chirurgicaux d’avant garde les plus récents sans oublier les résultats que nous avons obtenus dans un échantillon de 10 patients, l’état de l’art dans leur traitement chirurgical et notre expérience souligne l’importance d’un diagnostic précis et d’une sélection spécifique de la technique chirurgicale adéquate pour la prise en charge de la réparation biventriculaire chez les patients ayant une veine cave supérieure gauche s’abouchant à l’oreillette gauche en l’absence de sinus coronaire.
       
  • Common p2y 13 polymorphisms are associated with plasma inhibitory factor
           1 and lipoprotein(a) concentrations, heart rate and body fat mass: The
           GENES study
    • Abstract: Publication date: February 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 2Author(s): Céline Verdier, Jean-Bernard Ruidavets, Annelise Genoux, Guillaume Combes, Vanina Bongard, Dorota Taraszkiewicz, Michel Galinier, Meyer Elbaz, Jean Ferrières, Laurent O. Martinez, Bertrand PerretSummaryBackgroundThe P2Y13 purinergic receptor regulates hepatic high-density lipoprotein uptake and biliary sterol secretion; it acts downstream of the membrane ecto-F1-adenosine triphosphatase, which generates extracellular adenosine diphosphate that selectively activates P2Y13, resulting in high-density lipoprotein endocytosis. Previous studies have shown that the serum concentration of the F1-adenosine triphosphatase inhibitor inhibitory factor 1 is negatively associated with cardiovascular risk.AimTo evaluate whether p2y13 genetic variants affect cardiovascular risk.MethodsDirect sequencing of the p2y13 coding and flanking regions was performed in a subcohort of 168 men aged 45–74 years with stable coronary artery disease and 173 control subjects from the GENES study. The two most frequent mutations, rs3732757 and rs1466684, were genotyped in 767 patients with coronary artery disease and 789 control subjects, and their association with cardiovascular risk markers was analysed.ResultsCarriers of the rs3732757 261 T and rs1466684 557G alleles represented 9% and 27.5% of the entire population, respectively. The allele frequencies were identical in patients with coronary artery disease and control subjects. The presence of 261 T was associated with higher concentrations of plasma lipoprotein A-I and inhibitory factor 1, increased fat mass and a lower heart rate. Moreover, the proportion of patients with coronary artery disease with a pejorative systolic ankle − brachial index was lower in carriers of the 261 T allele. In both populations, the 557G allele was associated with increased concentrations of lipoprotein(a), and an allele dose effect was observed.ConclusionsTwo frequent p2y13 variants are associated with specific bioclinical markers of cardiovascular risk. Although neither one of these variants appears to be related to the development of atherosclerotic disease, they may modulate the risk of additional cardiovascular complications.RésuméContexteLe récepteur purinergique P2Y13 régule l’endocytose hépatique des HDL et la sécrétion des stérols biliaires. Il agit en aval de l’ecto-F1-ATPase membranaire dont l’activité génère de l’ADP extracellulaire qui stimule le récepteur P2Y13 puis l’endocytose HDL. Des études antérieures ont montré que le taux sérique de l’inhibiteur de la F1-ATPase, IF1, est négativement associé au risque cardiovasculaire.ObjectifÉvaluer si des variants génétiques de p2y13 affectent le risque cardiovasculaire.MéthodesLe séquençage direct de la partie codante de p2y13 a été réalisé dans une sous-cohorte de 168 patients coronariens stables, âgés de 45 à 74 ans, avec une coronaropathie stable (CAD) et chez 173 sujets témoins issus de l’étude GENES. Les deux mutations les plus fréquentes, rs3732757 et rs1466684, ont été génotypées dans 767 patients coronariens et 789 témoins de la cohorte, et leur association avec des marqueurs de risque cardiovasculaire a été analysée.RésultatsLes porteurs des allèles rs3732757 261 T et rs1466684 557G représentent respectivement 9 % et 27,5 % de l’ensemble de la population. Les fréquences alléliques sont identiques chez les patients atteints de coronaropathie et les sujets témoins. La présence de 261 T est associée à des niveaux plasmatiques plus élevés de LpA-I et IF1, à une augmentation de la masse grasse et à une fréquence cardiaque abaissée. De plus, la proportion de patients atteints de coronaropathie avec un index bras − cheville péjoratif était plus faible chez les porteurs d’allèles 261 T. Dans les deux populations, l’allèle 557G était associé à des taux accrus de Lp (a), et un effet dose d’allèle a été observé.ConclusionsDeux fréquents variants de p2y13 sont associés à des marqueurs biocliniques spécifiques du risque cardiovasculaire. Bien qu’aucun de ces variants ne semble être liée au développement de la maladie athéromateuse, ils pourraient moduler le risque de complications cardiovasculaires supplémentaires.
       
  • Percutaneous coronary interventions with the Absorb Bioresorbable vascular
           scaffold in real life: 1-year results from the FRANCE ABSORB registry
    • Abstract: Publication date: February 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 2Author(s): Guillaume Cayla, René Koning, Jean Fajadet, Joel Sainsous, Didier Carrié, Simon Elhadad, Francois Tarragano, Thierry Lefévre, Sylvain Ranc, Said Ghostine, Philippe Garot, Frédéric Marco, Luc Maillard, Pascal Motreff, Hervé Le Breton, FRANCE ABSORB investigatorsSummaryBackgroundSeveral randomized studies have shown that bioresorbable vascular scaffold (BVS) technology is associated with an increased risk of stent thrombosis.AimThis study aimed to assess the rates of adverse outcomes at 1 year in patients treated with the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA), using data from a large nationwide prospective multicentre registry (FRANCE ABSORB).MethodsAll patients receiving the Absorb BVS in France were included prospectively in the study. Predilatation, optimal sizing and postdilatation were recommended systematically. The primary endpoint was a composite of cardiovascular death, myocardial infarction and target lesion revascularization at 1 year. Secondary endpoints were scaffold thrombosis and target vessel revascularization at 1 year.ResultsA total of 2072 patients at 86 centres were included: mean age 55 ± 11 years; 80% men. The indication was acute coronary syndrome (ACS) in 49% of cases. Predilatation and postdilatation were done in 93% and 83% of lesions, respectively. At 1 year, the primary endpoint occurred in 3.9% of patients, the rate of scaffold thrombosis was 1.5% and the rate of target vessel revascularization was 3.3%. In a multivariable analysis, diabetes and total Absorb BVS length > 30 mm were independently associated with the occurrence of the primary endpoint, whereas oral anticoagulation and total Absorb BVS length > 30 mm were independently associated with occurrence of scaffold thrombosis.ConclusionsThe Absorb BVS was implanted in a relatively young population, half of whom had ACS. Predilatation and postdilatation rates were high, and 1-year outcomes were acceptable.RésuméContextePlusieurs études randomisées ont montré que l’implantation d’un stent bioresorbable (BVS) était associée à un risque accru de thrombose de stent.ObjectifL’objectif de cette étude était d’évaluer dans un large registre national multicentrique prospectif, l’efficacité et de sécurité à 1 an du stent bioresorbable Absorb.MéthodesTous les patients recevant un stent bioresorbable Absorb en France ont été prospectivement inclus dans l’étude. Une pré-dilatation, un calibrage optimal et une post-dilatation ont été systématiquement recommandés. Le critère principal de jugement était un critère composite associant décès cardiovasculaire, infarctus du myocarde et de revascularisation de la lésion cible à 1 an. Les critères secondaires étaient la thrombose de stent et la revascularisation du vaisseau cible à un an.RésultatsUn total de 2072 patients ont été inclus dans 86 centres, l’âge moyen était de 55 ± 11 ans ; 80% étaient des hommes. L’indication était un syndrome coronarien aigu (SCA) dans 49 % des cas. Des pré- et post-dilatations ont été réalisées respectivement dans 93 % et 83 % des lésions. Après un suivi de 1 an, le critère principal de jugement était de 3,9% ; le taux de thrombose de BVS était de 1,5 % et le taux de revascularisation du vaisseau cible était de 3,3 %. En analyse multivariée, le diabète et la longueur totale des BVS > 30 mm étaient indépendamment associées à la survenue du critère principal de jugement alors que l’anticoagulation orale et la longueur totale des BVS > 30 mm étaient indépendamment associées à la survenue d’une thrombose de stent.ConclusionsLes BVS ont été implantés dans une population relativement jeune, dont la moitié avait un SCA. Les taux de pré- et post-dilatation étaient élevés. Les résultats cliniques à un an étaient acceptables.
       
  • Long-term results of surgical treatment of secondary severe mitral
           regurgitation in patients with end-stage heart failure: Advantage of
           prosthesis insertion
    • Abstract: Publication date: February 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 2Author(s): Alexis Théron, Pierre Morera, Noémie Resseguier, Dominique Grisoli, Giulia Norscini, Alberto Riberi, Frédéric Collart, Gilbert Habib, Jean-François AvierinosSummaryBackgroundSurgical treatment of secondary mitral regurgitation (SMR) is controversial.AimTo analyse outcome after undersizing annuloplasty (UA) and mitral valve replacement (MVR).MethodsConsecutive patients operated on for severe SMR, with left ventricular ejection fraction (LVEF) 
       
  • How should we implement the recommendations of the Acute Cardiovascular
           Care Association in intensive cardiac care units in France'
    • Abstract: Publication date: February 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 2Author(s): François Roubille, Eric Bonnefoy, Etienne Puymirat, Meyer Elbaz, Patrick Henry, on behalf of the USIC Group (Emergency and Acute Cardiovascular Care group), a member of the Société française de cardiologie, the Acute Cardiovascular Care Association, the European Society of Cardiology
       
  • Hypercholesterolaemia and coronary artery disease: A silent killer with
           several faces
    • Abstract: Publication date: February 2019Source: Archives of Cardiovascular Diseases, Volume 112, Issue 2Author(s): Jean Ferrières
       
  • Letter in response to the article entitled “Position paper concerning
           the competence, performance and environment required in the practice of
           complex ablation procedures” by Maury et al.
    • Abstract: Publication date: Available online 19 January 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Walid Amara, Stephane Fromentin, François Jourda, Mohamed Belhameche, Saida Cheggour, Paul Bru, Antoine Milhem, Collège National des Cardiologues des Hôpitaux
       
  • Safeguarding continuing cardiovascular research excellence and quality
           publications in France: A working document from the French Society of
           Cardiology
    • Abstract: Publication date: Available online 10 January 2019Source: Archives of Cardiovascular DiseasesAuthor(s): Benjamin Alos, Mariama Akodad, Guillaume Avinee, Claire Bouleti, Pascale Chemaly, Cyrielle Desnos, Romain Didier, Rodrigue Garcia, Marianna Mirabel, Delphine Mika, Benoît Lattuca, Florent Le Ven, Vincent Probst, Martine GilardSummaryBackgroundFrance has a long history of successful cardiovascular research and scientific innovations, but its continued success cannot be taken for granted.AimsTo identify current obstacles to cardiovascular research in France and to crystallize the analysis into recommendations for maintained and enhanced research excellence in the future.MethodsThe French Society of Cardiology set up seven Working Groups, each comprising four to eight cardiologists, covering a spectrum of research institutes, hospitals, specialties, ages and research experience. The Working Groups met regularly in person or by conference call to analyse experiences, refine situation assessments and formulate recommendations for improvements. Results and suggestions were presented to a Core Team, which worked to synthesize, prioritize and organize the findings into a consolidated situation assessment and generate a set of action-orientated recommendations.ResultsFour key areas of action were identified: stronger focus on the generation of high-quality data; facilitation of future cardiovascular research; greater promotion and support for research among young cardiologists; and increased focus and support for communications. Most recommendations targeted structural shortcomings and may be implemented at low additional financial cost.ConclusionsIt is possible to maintain, and even increase, the quality of cardiovascular research in France and to boost the conversion of successful projects into high-impact publications, without major increases in funding. Intense collaboration between specialties and organizations is necessary to achieve sustainable results.RésuméObjectifsIdentifier les obstacles actuels à la recherche cardiovasculaire en France et cristalliser l’analyse en recommandations pour maintenir et améliorer l’excellence de la recherche dans l’avenir.MéthodesLa Société française de cardiologie a mis en place sept groupes de travail, chacun composé de quatre à huit cardiologues, couvrant un spectre d’instituts de recherche, d’hôpitaux, de spécialités, d’âges et d’expériences de recherche. Les groupes de travail se sont réunis régulièrement en personne ou par téléconférence pour réaliser l’état des lieux, affiner les évaluations de situation et formuler des recommandations. Les résultats et les suggestions ont été présentés à l’ensemble des membres de ces groupes qui s’est employé à synthétiser, hiérarchiser et organiser les conclusions en une évaluation consolidée de la situation et à formuler un ensemble de recommandations axées sur l’action.RésultatsQuatre domaines d’action clés ont été identifiés : mettre davantage l’accent sur la production de données de haute qualité ; faciliter la recherche cardiovasculaire future ; accroître la promotion et le soutien de la recherche chez les jeunes cardiologues ; et mettre davantage l’accent sur la communication et la soutenir. La plupart des recommandations visaient des lacunes structurelles et pouvaient être mises en œuvre à faible coût financier supplémentaire.ConclusionsIl est possible de maintenir, voire d’améliorer, la qualité de la recherche cardiovasculaire en France et de dynamiser la conversion de projets réussis en publications à fort impact, sans une augmentation trop importante du financement. Une collaboration intense entre les spécialités et les organisations est nécessaire pour obtenir des résultats durables.
       
  • Lessons from MITRA-FR and COAPT studies: Can we hope for an indication for
           severe functional mitral regurgitation in systolic heart failure'
    • Abstract: Publication date: Available online 31 December 2018Source: Archives of Cardiovascular DiseasesAuthor(s): Yves Juillière
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.227.2.246
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-